Ligand Pharmaceuticals (LGND) Earnings Date, Estimates & Call Transcripts $146.32 +3.92 (+2.75%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$146.50 +0.19 (+0.13%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ligand Pharmaceuticals Earnings Summary Ligand Pharmaceuticals released Q1 2025 earnings on May 8, 2025, reporting an EPS of $1.33, which beat analysts' consensus estimates of $1.23 by $0.10. Quarterly revenue was reported to be $45.33 million, above analyst estimates of $37.84 million. With a trailing EPS of -$7.12, Ligand Pharmaceuticals' earnings are expected to grow 114.45% next year, from $1.73 to $3.71 per share. Latest Q1 Earnings DateMay. 8EstimatedConsensus EPS (May. 8) $1.23 Actual EPS (May. 8) $1.33 Beat By $0.10 Actual Revenue (May. 8) $45.33MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Ligand Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ligand Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataLGND Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LGND Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ligand Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany EPS GuidanceCompany Revenue GuidanceQ1 20251$0.98$0.98$0.98Q2 20251$1.01$1.01$1.01Q3 20251$1.00$1.00$1.00 2025 3 $2.99 $2.99 $2.99 Q1 20261$1.19$1.19$1.19 Ligand Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025$1.23$1.33+$0.10-$2.21$37.84M$45.33M8/6/2024Q2 2024$1.06$1.40+$0.34$4.72$33.04M$41.50M5/7/2024Q1 2024$0.83$3.84+$3.01-$3.15$27.92M$30.90M2/27/2024Q4 2023$0.24$0.79+$0.55$0.55$24.54M$28.10M11/8/2023Q3 2023$0.68$1.02+$0.34$2.16$27.22M$32.87M8/8/2023Q2 2023$0.76$1.42+$0.66$2.07$24.74M$26.37M Ligand Pharmaceuticals Earnings - Frequently Asked Questions When did Ligand Pharmaceuticals announce their last quarterly earnings? Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earning data on Thursday, May 8, 2025. Learn more on LGND's earnings history. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY 2025 earnings guidance on Thursday, August, 7th. The company provided earnings per share (EPS) guidance of 6.700-7.000 for the period, compared to the consensus EPS estimate of 6.123. The company issued revenue guidance of $200.0 million-$225.0 million, compared to the consensus revenue estimate of $194.0 million. Did Ligand Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Ligand Pharmaceuticals (NASDAQ:LGND) reported $1.33 earnings per share (EPS) to beat the analysts' consensus estimate of $1.23 by $0.10. Learn more on analysts' earnings estimate vs. LGND's actual earnings. How can I listen to Ligand Pharmaceuticals' earnings conference call? The conference call for Ligand Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Ligand Pharmaceuticals' conference call transcript? The conference call transcript for Ligand Pharmaceuticals' latest earnings report can be read online. Read Transcript How much revenue does Ligand Pharmaceuticals generate each year? Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded annual revenue of $181.49 million. How much profit does Ligand Pharmaceuticals generate each year? Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded net income of -$4.03 million. LGND has generated -$7.12 earnings per share over the last four quarters. What is Ligand Pharmaceuticals' EPS forecast for next year? Ligand Pharmaceuticals' earnings are expected to grow from $1.73 per share to $3.71 per share in the next year, which is a 114.45% increase. More Earnings Resources from MarketBeat Related Companies ADMA Biologics Earnings ANI Pharmaceuticals Earnings Exelixis Earnings Exact Sciences Earnings Halozyme Therapeutics Earnings Ionis Pharmaceuticals Earnings Madrigal Pharmaceuticals Earnings Repligen Earnings Alkermes Earnings Amicus Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a RallyRivian Takes Earnings Hit—R2 Could Be the Stock's 2026 LifelinePalantir Stock Soars After Blowout Earnings ReportVertical Aerospace's New Deal and Earnings De-Risk Production This page (NASDAQ:LGND) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
